No attachments available.
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer’s disease and mild to moderate traumatic brain injury
Contact and place of performance
fred Ettehadieh
GBR
Clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet (ECRT) formulation in early mild Alzheimer's disease and mild to moderate traumatic brain injury. IDIQ Contract No. 75N95024D00002 IDIQ Contract Award Dollar Amount: $962,486.00 Minimum Order; $1,988,692.00 Maximum Order Limitation
The National Institutes of Health NIDA has awarded an Indefinite Delivery/Indefinite Quantity contract for the clinical evaluation of Phenserine tartrate Extended Controlled Release Tablet formulations. This project focuses on the evaluation of these formulations in patients with early mild Alzheimer’s disease and mild to moderate traumatic brain injury. The work is classified under NAICS 541990 All Other Professional, Scientific, and Technical Services and PSC B504 Special Studies/Analysis- Chemical/Biological.
The contract, identified as 75N95024D00002 following solicitation 75N95022R00041, establishes a minimum order amount of $962,486.00 and a maximum order limitation of $1,988,692.00. Primary performance will take place in the United Kingdom. The award notice was published on January 31, 2024, listing Fred Ettehadieh as the point of contact. There are zero attachments associated with this notice.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.